Prevention and treatment of recurrent upper respiratory tract infections in children

Abstract

Upper respiratory tract infections are the most common reason for medical consultations. Children may develop a respiratory tract infection even several times a year. The most common etiological factor is viruses, and such infections require symptomatic treatment. Only some cases of infections caused by influenza virus and RSV may be treated with antiviral drugs. This article focuses on drugs that have proven clinical efficacy in the prevention and symptomatic treatment of upper respiratory tract infections. Natural herbal medicines are also mentioned as alternative treatments that can bring relief and reduce symptom severity and duration.

Piśmiennictwo

1. Bernatowska E, Feleszko W, Cukrowska B i wsp. Immunomodulacja w wieku rozwojowym w praktyce lekarza podstawowej opieki zdrowotnej – fakty i mity. Pediatr Dypl 2013;17(1):27-37.

2. Monto AS. Epidemiology of viral respiratory infections. Am J Med 2002;112(Suppl. 6A):4S-12S.

3. Hryniewicz W, Radzikowski A, Albrecht P i wsp. Narodowy Program Ochrony Antybiotyków. Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Narodowy Instytut Leków, Warszawa 2016. http://www.antybiotyki.edu.pl/pdf/Rekomendacje2016.pdf.

4. Wirtualna Akademia Grypy. www.wirtualnaakademiagrypy.pl.

5. Norhayati MN, Ho JJ, Azman MY. Influenza vaccines for preventing acute otitis media in infants and children. Cochrane Database Syst Rev 2015;3:CD010089.

6. Goodridge HS, Ahmed SS, Curtis N, et al. Harnessing the beneficial heterologous effects of vaccination. Nat Rev Immunol 2016;16(6):392-400.

7. Yakoob MY, Salam RA, Khan FR, et al. Vitamin D supplementation for preventing infections in children under five. Cochrane Database of Syst Rev 2016;11:CD008824.

8. Aglipay M, Birken CS, Parkin PC. Effect of high-dose vs standard-dose wintertime vitamin D supplementation on viral upper respiratory tract infections in young healthy children, JAMA 2017,318(3):245-54.

9. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583.

10. Autier P, Mullie P, Macacu A, et al. Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials. doi: http://dx.doi.org/10.1016/S2213-8587(17)30357-1.

11. Płudowski P, Karczmarewicz E, Chlebna-Sokół i wsp. Witamina D: Rekomendacje dawkowania w populacji osób zdrowych oraz w grupach ryzyka deficytów – wytyczne dla Europy Środkowej 2013 r. Standardy Medyczne/Pediatria 2013,10:573-8.

12. Kearney SC, Dziekiewicz M, Feleszko W. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory respiratory infections and asthma. Ann Allergy Asthma Immunol 2015;114(5):364-9.

13. Giovannini M, Salvini F, Riva E. Bacterial extracts as immunomodulators for the prevention of recurrent respiratory infections in children. J Med Microb Diagn 2014;3:136. doi: 10.4172/2161-0703.1000136.

14. Cazzola M, Anapurpau S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis. Pulm Pharmacol Ther 2012;25(1):62-8. doi:10.1016/j.pupt.2011.11.002.

15. Del-Rio-Navarro BE, Espinosa-Rosales F, Flenady V, et al. Immunostimulants for preventing respiratory tract infection in children. Evid Based Child Health 2012;7(2):629-717.

16. Fokkens W, Lund V, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps. Otorynolaryngologia 2013,12(2):60-71.

17. Ricci R, Palmero C, Bazurro G, et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulm Pharmacol Ther 2014;27(1):109-13. doi: 10.1016/j.pupt.2013.05.006. Epub 2013 Jun 21.

18. Braido F, Tarantini F, Ghiglione V, et al. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis 2007;2(3):335-45.

19. Bitar MA, Saade R. The role of OM-85 BV (Broncho-Vaxom) in preventing recurrent acute tonsillitis in children. Int J Pediatr Otorhinolaryngol 2013 May;77(5):670-3. doi: 10.1016/j.ijporl.2013.01.009. Epub 2013 Feb 4.

20. Pan L, Jiang XG, Guo J, et al. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Clin Pharmacol 2015;55(10):1086-92.

21. Koatz AM, Coe NA, Cicerán A, et al. Clinical and immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections. Lung 2016;194(4):687-97.

22. Zagólski O, Stręk P, Kasprowicz A, et al. Effectiveness of polyvalent bacterial lysate and autovaccines against upper respiratory tract bacterial colonization by potential pathogens: a randomized study. Med Sci Monit 2015;21:2997-3002. Published online 2015 Oct 5. doi: 10.12659/MSM.893779. PMCID: PMC4599189.

23. Ismigen. Charakterystyka produktu leczniczego. https://pl.gsk.com/media/729232/ismigen-chpl-01012016-plus-korekta-02092016.pdf.

24. Broncho-Vaxom. Ulotka dla pacjenta: informacja dla użytkownika. https://pub.rejestrymedyczne.csioz.gov.pl/Pobieranie.ashx?type=1171-u.

25. Luivac. Charakterystyka produktu leczniczego. https://gdziepolek.blob.core.windows.net/product-documents/doc13068/luivac-dokument.pdf.

26. Ribomunyl. Charakterystyka produktu leczniczego. https://lekomanprod.blob.core.windows.net/product-documents/doc20990/ribomunyl-dokument.pdf.

27. Polyvaccinum mite. Ulotka dołączona do opakowania: informacja dla pacjenta. https://www.biomed.pl/resources/document/Ulotki_PDF/Polyvaccinum_mite_krople_do_nosa.1.pdf.

28. Unger SA, Bogaert D. The respiratory microbiome and respiratory infections. J Infect 2017;74 Suppl 1:S84-S88.

29. Purchiaroni F, Tortora A, Gabrielli M, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013;17(3):323-33.

30. Wang Y, Li X, Ge T, et al. Probiotics for prevention and treatment of respiratory tract infections in children: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95(31):e4509.

31. Amaral MA, Guedes GHBF, Epifanio M, et al. Network meta-analysis of probiotics to prevent respiratory infections in children and adolescents. Pediatr Pulmonol 2017;52(6):833-43.

32. Hyink O, Wescombe PA, Upton M, et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 2007;73(4):1107-13.

33. Di Pierro F, Adami T, Rapacioli G, et al. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther 2013;13(3):339-43.

34. Di Pierro F, Colombo M, Zanvit A, et al. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug, Healthc Patient Saf 2014;6:15-20.

35. Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J General Medicine 2012;5:991-7.

36. Jesenak M, Urbancikova I, Banovcin P. Respiratory tract infections and the role of biologically active polysaccharides in their management and prevention. Nutrients 2017;9(7):E779.

37. Bashir KMI, Choi JS. Clinical and physiological perspectives of β-glucans: the past, present, and future. Int J Mol Sci 2017;18(9):E1906.

38. Radzikowski A, Albrecht P. Leczenie objawowe zakażeń dróg oddechowych – podstawy patofizjologiczne i strategia postępowania. Pediatr Pol 1998;73:1-8.

39. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother 2010;44(3):489-506.

40. Wong T, Stang AS, Ganshorn H, et al. Combined and alternating paracetamol and ibuprofen therapy for febrile children. Cochrane Database Syst Rev 2013;10:CD009572.

41. Hayward G, Heneghan C, Perera R. et al. Intranasal corticosteroids in management of acute sinusitis: a systematic review and meta-analysis. Ann Fam Med 2012;10(3):241-9.

42. De Sutter AI, Lemiengre M, Campbell H, et al. Antihistamines for the common cold. Cochrane Database Syst Rev 2003;3:CD001267.

43. Zanasi A, Lanata L, Fontana G, et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med 2015;10(1):19. doi: 10.1186/s40248-015-0014-3.

44. Oduwole O, Meremikwu MM, Oyo-Ita A, et al. Honey for acute cough in children. Cochrane Database Syst Rev 2012;3:CD007094.

45. Tanzi MG, Gabay MP. Association between honey consumption and infant botulism. Pharmacotherapy 2002;22(11):1479-83.

46. Miceli Sopo S, Greco M, Monaco S, et al.; Milk Honey Study (M&HS) Group. Effect of multiple honey doses on non-specific acute cough in children. An open randomized study and literature review. Allergol Immunopathol (Madr) 2015;43(5):449-55.

47. Balli F, Bergamini B, Calistru P, et al. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Ther 2007;45(1):16-22.

48. Zhang L, Mendoza-Sassi RA, Klassen TP, et al. Nebulized hypertonic saline for acute bronchiolitis: a systematic review. Pediatrics 2015:136(4):687-701.

49. Lamer-Zarawska E, Kowal-Gierczak B, Niedworok J. Fitoterapia i leki roślinne. PZWL, Warszawa 2007.

50. Bolbot Y, Prokhorov E, Mokia S, et al. Comparing the efficacy and safety of high-concentrate (5-7.5:1) ivy leaves extract and acetylcysteine for treatment of children with acute bronchitis. Drugs of Ukraine 2004;11:1-4.

51. Koch AK, Klose P, Lauche R, et al. A systematic review of phytotherapy for acute rhinosinusitis. Forsch Komplementmed 2016;23:165-9. doi: 10.1159/000447467.

52. Anheyer D, Holger C, Romy L, et al. Herbal medicine in children with respiratory tract infection: systematic review and meta-analysis. Acad Ped 2018;18(1):8-19. http://dx.doi.org/10.1016/j.acap.2017.06.006.

53. Ulbricht C, Basch E, Cheung L, et al. An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration. J Diet Suppl 2014;11(1):80-120.

54. Lasek W, Janyst M, Wolny R, et al. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm 2015;65(2):171-80. doi: 10.1515/acph-2015-0015.

55. You Y, Wang L, Li Y, et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol 2015;42(6):596-601. doi: 10.1111/1346-8138.12845.

56. Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis 2016;16(1):648.

57. Hu XY, Wu RH, Logue M, et al. Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis. PLOS ONE 2017;12(8):e0181780. doi:10.1371/journal.pone.0181780.

58. Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006,2:CD001169.

59. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007;44(2):197-202.

60. Matheson N, Harnden AR, Perera R, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007;1:CD002744.

61. Tamiflu. Charakterystyka produktu leczniczego. http://www.roche.pl/content/dam/roche_poland/pl_PL/documents/SmPC/tamiflu_kapsulki.pdf.

Do góry